Olema Oncology to Present at 43rd Annual J.P. Morgan Healthcare Conference
Olema Pharmaceuticals (Nasdaq: OLMA), a clinical-stage biopharmaceutical company specializing in targeted therapies for breast cancer, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. Sean P. Bohen, M.D., President and Chief Executive Officer, will deliver a presentation on Tuesday, January 14, 2025, at 3:45 p.m. PT (6:45 p.m. ET) in San Francisco, California.
The presentation will be accessible via live webcast, along with any accompanying materials, through the Events and Presentations section of Olema's Investor Relations website at ir.olema.com. A recording will also be made available at the same location following the presentation.
Olema Pharmaceuticals (Nasdaq: OLMA), un'azienda biofarmaceutica in fase clinica specializzata in terapie mirate per il cancro al seno, ha annunciato la sua partecipazione alla 43ª Conferenza Sanitaria Annuale J.P. Morgan. Sean P. Bohen, M.D., Presidente e Amministratore Delegato, terrà una presentazione martedì 14 gennaio 2025, alle 15:45 PT (18:45 ET) a San Francisco, California.
La presentazione sarà accessibile tramite webcast dal vivo, insieme a eventuali materiali di accompagnamento, attraverso la sezione Eventi e Presentazioni del sito web delle Relazioni con gli Investitori di Olema all'indirizzo ir.olema.com. Una registrazione sarà inoltre disponibile nello stesso luogo dopo la presentazione.
Olema Pharmaceuticals (Nasdaq: OLMA), una empresa biofarmacéutica en etapa clínica especializada en terapias dirigidas para el cáncer de mama, ha anunciado su participación en la 43ª Conferencia Anual de Salud J.P. Morgan. Sean P. Bohen, M.D., Presidente y Director Ejecutivo, realizará una presentación el martes 14 de enero de 2025, a las 3:45 p.m. PT (6:45 p.m. ET) en San Francisco, California.
La presentación se podrá acceder a través de un webcast en vivo, junto con cualquier material adicional, a través de la sección de Eventos y Presentaciones en el sitio web de Relaciones con Inversores de Olema en ir.olema.com. También se pondrá a disposición una grabación en el mismo lugar después de la presentación.
Olema Pharmaceuticals (Nasdaq: OLMA)는 유방암을 위한 표적 치료에 특화된 임상 단계의 바이오 제약 회사로, 제43회 연례 J.P. Morgan 헬스케어 컨퍼런스에 참석한다고 발표했습니다. Sean P. Bohen, M.D., 사장 겸 CEO는 2025년 1월 14일 화요일 오후 3시 45분 PT(동부 표준시 오후 6시 45분)에 캘리포니아주 샌프란시스코에서 발표를 할 예정입니다.
발표는 Olema의 투자자 관계 웹사이트 ir.olema.com의 이벤트 및 프레젠테이션 섹션을 통해 라이브 웹캐스트로 시청할 수 있습니다. 발표 후에는 동일한 위치에서 녹화본도 제공될 것입니다.
Olema Pharmaceuticals (Nasdaq: OLMA), une entreprise biopharmaceutique en phase clinique spécialisée dans les thérapies ciblées pour le cancer du sein, a annoncé sa participation à la 43e Conférence Annuelle J.P. Morgan sur la Santé. Sean P. Bohen, M.D., Président et Directeur Général, fera une présentation le mardi 14 janvier 2025, à 15h45 PT (18h45 ET) à San Francisco, Californie.
La présentation sera accessible via un webcast en direct, ainsi que tout matériel d'accompagnement, à travers la section Événements et Présentations du site de Relations avec les Investisseurs d'Olema à l'adresse ir.olema.com. Un enregistrement sera également disponible au même endroit après la présentation.
Olema Pharmaceuticals (Nasdaq: OLMA), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf gezielte Therapien gegen Brustkrebs spezialisiert hat, hat seine Teilnahme an der 43. Annual J.P. Morgan Healthcare Conference bekannt gegeben. Sean P. Bohen, M.D., Präsident und Chief Executive Officer, wird am Dienstag, den 14. Januar 2025, um 15:45 Uhr PT (18:45 Uhr ET) in San Francisco, Kalifornien, eine Präsentation halten.
Die Präsentation wird über einen Live-Webcast sowie begleitende Materialien über den Abschnitt Veranstaltungen und Präsentationen der Investor-Relations-Website von Olema unter ir.olema.com zugänglich sein. Eine Aufzeichnung wird nach der Präsentation an derselben Stelle zur Verfügung stehen.
- None.
- None.
SAN FRANCISCO, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that Sean P. Bohen, M.D., President and Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, California, on Tuesday, January 14, 2025 at 3:45 p.m. PT (6:45 p.m. ET).
A live webcast of the presentation and any accompanying materials will be available under the Events and Presentations section of Olema’s Investor Relations website at ir.olema.com. A recording of the presentation will be made available in the same location.
About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), currently in a Phase 3 clinical trial called OPERA-01. In addition, Olema is developing a potent KAT6 inhibitor (OP-3136). Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit us at www.olema.com.
Media and Investor Relations Contact
Courtney O’Konek
Vice President, Corporate Communications
Olema Oncology
media@olema.com
FAQ
When is Olema Pharmaceuticals (OLMA) presenting at the 2025 J.P. Morgan Healthcare Conference?
How can investors watch Olema's (OLMA) presentation at the J.P. Morgan Healthcare Conference?
Who will represent Olema Pharmaceuticals (OLMA) at the 2025 J.P. Morgan Healthcare Conference?
What is the main focus of Olema Pharmaceuticals' (OLMA) research and development?
